Literature DB >> 9732695

LY294002-mediated inhibition of phosphatidylinositol 3-kinase activity triggers growth inhibition and apoptosis in CD40-triggered Ramos-Burkitt lymphoma B cells.

A P Curnock1, K A Knox.   

Abstract

Cells of the Epstein-Barr virus genome-negative Ramos-Burkitt lymphoma (Ramos-BL) B cell line can be rescued from antigen receptor (AgR)-triggered growth inhibition and apoptosis by signals transduced through their surface CD40. This study investigates whether phosphatidylinositol 3-kinase (PI3-kinase), which has been reported to be intimately involved in the regulation of normal and neoplastic cell growth, plays a role in CD40-promoted Ramos-BL B cell survival and uses the selective and reversible PI3-kinase inhibitor, LY294002 (LY). LY-mediated inhibition of PI3-kinase activity triggers growth inhibition and leads to the processing of caspase-3, caspase-3-like activity, cleavage of the death substrate poly(ADP-ribose) polymerase (PARP), and apoptosis from the G1 phase of cell cycle. These data indicate that constitutive PI3-kinase activity is critical for Ramos-BL B cell progression through the cell cycle such that if this PI3-kinase-dependent pathway(s) is inhibited, the cells default to apoptosis. Signals transduced through CD40 abrogate LY-triggered caspase-3-like activity and PARP cleavage but fail to inhibit LY-triggered growth inhibition, processing of caspase-3, and apoptosis. Likewise, in the presence of LY, signals transduced through CD40 abrogate AgR-triggered caspase-3-like activity and PARP cleavage but fail to inhibit AgR-triggered growth inhibition, caspase-3 processing, and apoptosis. The LY-mediated induction of growth inhibition and apoptosis occurs in the presence of the CD40-induced anti-apoptotic protein Bcl-XL. Taken together these data indicate that the CD40 of Ramos BL B cells is linked to PI3-kinase-independent and -dependent routes of survival: CD40-mediated inhibition of AgR-triggered caspase-3-like activity, PARP cleavage, and CD40-triggered Bcl-XL expression are PI3-kinase-independent, whereas PI3-kinase is critical for CD40-mediated rescue of this cellular population from AgR-triggered growth inhibition, caspase-3 processing, and apoptosis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9732695     DOI: 10.1006/cimm.1998.1335

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  9 in total

1.  Pivotal advance: CEACAM1 is a negative coreceptor for the B cell receptor and promotes CD19-mediated adhesion of B cells in a PI3K-dependent manner.

Authors:  Elizabeth O Lobo; Zhifang Zhang; John E Shively
Journal:  J Leukoc Biol       Date:  2009-05-19       Impact factor: 4.962

2.  2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process.

Authors:  Ning Gao; Mohamed Rahmani; Paul Dent; Steven Grant
Journal:  Oncogene       Date:  2005-05-26       Impact factor: 9.867

3.  Phosphoinositide 3-kinase-dependent Ras activation by tauroursodesoxycholate in rat liver.

Authors:  A K Kurz; C Block; D Graf; S V Dahl; F Schliess; D Häussinger
Journal:  Biochem J       Date:  2000-08-15       Impact factor: 3.857

4.  Pan-class I  PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53.

Authors:  Anja Müller; Bernd Gillissen; Antje Richter; Anja Richter; Cindrilla Chumduri; Peter T Daniel; Christian W Scholz
Journal:  Cell Death Dis       Date:  2018-03-07       Impact factor: 8.469

5.  Phosphoinositide 3-kinase/AKT/mTORC1/2 signaling determines sensitivity of Burkitt's lymphoma cells to BH3 mimetics.

Authors:  Lindsay C Spender; Gareth J Inman
Journal:  Mol Cancer Res       Date:  2012-01-12       Impact factor: 5.852

6.  A monoclonal antibody to the alpha2 domain of murine major histocompatibility complex class I that specifically kills activated lymphocytes and blocks liver damage in the concanavalin A hepatitis model.

Authors:  Shuji Matsuoka; Hiromichi Tsurui; Masaaki Abe; Kazuo Terashima; Kazuhiro Nakamura; Yoshitomo Hamano; Mareki Ohtsuji; Nakayuki Honma; Isao Serizawa; Yasuyuki Ishii; Masafumi Takiguchi; Sachiko Hirose; Toshikazu Shirai
Journal:  J Exp Med       Date:  2003-07-28       Impact factor: 14.307

Review 7.  Developments in Burkitt's lymphoma: novel cooperations in oncogenic MYC signaling.

Authors:  Lindsay C Spender; Gareth J Inman
Journal:  Cancer Manag Res       Date:  2014-01-09       Impact factor: 3.989

8.  Establishment of a Therapeutic Anti-Pan HLA-Class II Monoclonal Antibody That Directly Induces Lymphoma Cell Death via Large Pore Formation.

Authors:  Shuji Matsuoka; Yasuyuki Ishii; Atsuhito Nakao; Masaaki Abe; Naomi Ohtsuji; Shuji Momose; Hui Jin; Hisashi Arase; Koichi Sugimoto; Yusuke Nakauchi; Hiroshi Masutani; Michiyuki Maeda; Hideo Yagita; Norio Komatsu; Okio Hino
Journal:  PLoS One       Date:  2016-03-30       Impact factor: 3.240

9.  Treatment response to idelalisib in a patient with immunodeficiency-associated Burkitt lymphoma harboring a PIK3CA H1047R mutation.

Authors:  Annalen Bleckmann; Sascha Dierks; Hans-Ulrich Schildhaus; Niels Hellige; Ulrike Bacher; Lorenz Trümper; Gerald Wulf
Journal:  Ann Hematol       Date:  2020-03-20       Impact factor: 3.673

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.